Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients
NCT ID: NCT07315139
Last Updated: 2026-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
42 participants
INTERVENTIONAL
2023-02-01
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients
NCT00285298
Efficacy of Pentoxifylline on Chronic Kidney Disease
NCT00155246
A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function
NCT00596518
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
NCT07315360
Pentoxifylline and Systemic Inflammation in Hemodialysis Patients
NCT01269827
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The diagnosis of CKD is established by laboratory testing, most often by estimating glomerular filtration rate (GFR) from a filtration marker, such as serum creatinine or cystatin C, using various formulas, or by testing urine for albumin or protein (or both).
Pentoxifylline (PTX), a synthetic dimethylxanthine derivative used initially to treat intermittent claudication in patients with peripheral arterial disease due to its hemorheological effects, has been shown to have potent antioxidant, anti-inflammatory, antidiabetic, anti-cellular-damage, and antifibrotic effects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Patients received the standard therapy. The routine standard consisted of angiotensin-converting enzyme inhibitors (ACEI) (Ramipril 1.25 mg), a calcium-based phosphate binder (calcium acetate 700 mg, containing 180 mg of calcium), alfacalcidol (0.25 µg), antihypertensive medications, and diuretics.
Angiotensin-converting enzyme inhibitors (Ramipril)
Patients received the standard therapy. The routine standard consisted of angiotensin-converting enzyme inhibitors (ACEI) (Ramipril 1.25 mg), a calcium-based phosphate binder (calcium acetate 700 mg, containing 180 mg of calcium), alfacalcidol (0.25 µg), antihypertensive medications, and diuretics.
Group 2
Patients received one capsule of Pentoxifylline 400 mg twice daily for 6 months, in addition to their standard therapy.
Pentoxifylline
Patients received one capsule of Pentoxifylline 400 mg twice daily for 6 months, in addition to their standard therapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Angiotensin-converting enzyme inhibitors (Ramipril)
Patients received the standard therapy. The routine standard consisted of angiotensin-converting enzyme inhibitors (ACEI) (Ramipril 1.25 mg), a calcium-based phosphate binder (calcium acetate 700 mg, containing 180 mg of calcium), alfacalcidol (0.25 µg), antihypertensive medications, and diuretics.
Pentoxifylline
Patients received one capsule of Pentoxifylline 400 mg twice daily for 6 months, in addition to their standard therapy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* Patients with chronic kidney disease (CKD) stages G3, G4.
* Patients with proteinuria \< 1 g.
Exclusion Criteria
* Patients with Diabetes mellitus.
* Patients with proteinuria \> 1 g.
* Patients with a history of hemodialysis.
* Patients with active infection or hospitalized.
* Patients with recent cerebral and /or retinal Hemorrhage.
* Patients taking warfarin or theophylline-containing drugs.
* women who are taking oral contraceptives, pregnant, or lactating
* Patients with a history of adverse reactions to Pentoxifylline.
* Patients with polycystic kidney disease.
* Patients with obstructive uropathy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ashraf Hassan
Assistant Professor of Internal Medicine and Nephrology, Faculty of Medicine, Ain shams University, Cairo, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU MS 53/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.